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Immunodeﬁciency Virus Coinfected
Patients
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Mzudumile R. Ngwanya,1 Gail Todd,1 and Keertan Dheda2
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HIV Medicine, Department of Medicine, and 4Department of Paediatrics and Child Health,
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Elimination of a rifamycin from the treatment regimen for
tuberculosis negatively impacts outcomes. Cross-reactivity be-
tween the rifamycins after drug eruptions is unclear. We report
6 consecutive human immunodeﬁciency virus-infected patients
with rifampicin-associated drug rash with eosinophilia and sys-
temic symptoms (DRESS) syndrome conﬁrmed on diagnostic re-
challenge. The patients subsequently tolerated rifabutin. These
data inform clinical management of tuberculosis-associated
drug reactions.
Keywords. alternative; rifabutin; rifampicin-associated
drug eruption; tuberculosis HIV coinfection.
Tuberculosis (TB) is a major cause of mortality in sub-Saharan
Africa [1]. The upsurge in the incidence of TB in recent years
has been driven by the human immunodeﬁciency virus (HIV)
pandemic. In 2013, 61% of new cases of TB in South Africa were
coinfected with HIV [2]. Cutaneous adverse drug reactions
(CADRs) are generally more common in persons infected
with HIV, including those associated with 1st-line anti-TB
drugs (FLTDs) [3].
All FLTDs can cause a wide variety of CADRs, including drug
rash with eosinophilia and systemic symptoms (DRESS syn-
drome), a severe form of CADR with mortality of up to 10%
[4]. The diagnosis of DRESS syndrome warrants interruption
of treatment that may impact cure and survival [3]. We have
previously shown that diagnostic rechallenge in the context of
FLTD, even in severe CADR such as DRESS syndrome and
toxic epidermal necrolysis, is usually successful, and the major-
ity of rechallenge reactions are nonlife threatening. Rechallenge
facilitates detection of the offending drug allowing its removal
from the treatment regimen while retaining the other FLTD
within the treatment regimen [5]. This improves outcomes in
the management of TB, because 2nd-line drugs are less efﬁca-
cious and are associated with higher toxicity proﬁles [3].
The rifamycins are a class of synthetic antibiotics particularly
effective against mycobacteria. Rifampicin, rifabutin, rifapen-
tine, and rifaximin are the currently available rifamycins.
Their inclusion in the treatment regimen for TB has been
shown to shorten the duration of therapy, improve cure rates,
and lower relapse rates [6]. Thus, elimination of rifampicin in
the context of CADR often impacts negatively on treatment out-
comes. For that reason, it would be useful if rifampicin could be
substituted with an alternative rifamycin.
However, there are limited data about the cross-reactivity
among the rifamycins in the context of CADR. We report the
successful switch to rifabutin as an alternative to rifampicin
in a series of patients with rifampicin-associated DRESS
syndrome.
METHODS
The subjects included in this study had initially presented to the
dermatology ward at Groote Schuur Hospital, a tertiary center
in Cape Town, South Africa, with CADR while on FLTDs be-
tween November 2013 and June 2015. They were all enrolled in
a larger randomized controlled trial comparing sequential, ad-
ditive, and incremental dosing versus sequential, additive, and
full therapeutic dose reintroduction of FLTD in CADR. That
study, now completed, was approved by the institutional
Human Research Ethics Committee (Reference: 246/2009).
The methods used in the parent study have previously been de-
scribed [7, 8]. Eighty-eight patients were rechallenged with ri-
fampicin in the parent study, and 19 of 88 (22%) patients
reacted to rifampicin. Based on recently published literature,
the last 6 consecutive cases of the 19 who reacted to rifampicin
were switched to rifabutin [9, 10].
On admission, the anti-TB drugs were stopped when TB-
associated CADR was suspected. Before rechallenge, all patients
were investigated to conﬁrm active TB. Once the CADR had re-
solved and laboratory parameters returned to baseline, three
2nd-line anti-TB drugs (SLTDs) to which the patient has not
previously been exposed were initiated as bridge therapy. This
was to minimize the risk of developing mycobacterial resistance
during the prolonged rechallenge process with the individual
drugs. This was followed by a diagnostic workup (patch testing
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followed by a skin prick test and an oral rechallenge) to pinpoint
the offending FLTD. Depending on the sensitivities of the pa-
tient’s strain of TB, isoniazid followed by rifampicin, pyrazina-
mide, and ethambutol were reintroduced consecutively and
additively. A rechallenge reaction after any of these modalities
lead to immediate withdrawal of the drug from the treatment
regimen. The last 6 cases of the study that developed rechallenge
reactions to rifampicin were switched to oral therapeutic dose of
rifabutin after completion of the rechallenge process. The other
FLTD that did not induce a rechallenge reaction were continued
uninterrupted. Laboratory parameters and clinical features usu-
ally associated with a drug reaction were closely monitored for
96 hours after initiating rifabutin.
RESULTS
The demographic and clinical characteristics of the 6 patients
with DRESS syndrome that developed rechallenge reactions to
rifampicin and subsequently tolerated rifabutin are summarized
in Table 1. All 6 participants were TB and HIV coinfected (me-
dian CD4 count 111 cells/mm3). Three of them had pulmonary
TB and 3 had disseminated disease. One had previous TB before
the current episode, and none had a previous drug reaction. Five
of the 6 participants were determined not to be resistant to ri-
fampicin by GeneXpert MTB/RIF assay before they were started
on anti-TB therapy. Two were on antiviral therapy (ART),
which was initially interrupted but reinitiated uneventfully.
Four of the 6 were on co-trimoxazole for Pneumocystis jiroveci
pneumonia prophylaxis at the onset of CADR, which was
stopped and not reinitiated. All 6 fulﬁlled the diagnostic criteria
of DRESS syndrome at initial presentation as deﬁned by
Bocquet et al [11].
The rechallenge reactions to rifampicin were characterized by
a rash in 6 of 6 (100%), itch and eosinophilia in 5 of 6 (83%)
each, hepatitis in 4 of 6 (67%), edema in 3 of 6 (50%), and
fever, hypotension, and diarrhea once. They were treated with
potent topical steroids until resolution. None received systemic
steroids. All 6 cases developed multiple drug hypersensitivity to
at least 2 anti-TB drugs (Table 1). Three of the 6 cases reacted to
2 FLTD and required more than the standard 6 months of treat-
ment. The other 3 reacted to rifampicin and at least 1 SLTD, but
they were successfully rechallenged with the other 3 FLTDs
(isoniazid, pyrazinamide, and ethambutol). Consequently, the
Table 1. Demographic and Clinical Characteristics of Six Cases of Tuberculosis-Associated DRESS That Developed Rechallenge Reactions to Rifampicin
and Tolerated Rifabutin
Case
Age in
Years Gender
CD4
Count
(Cells/
mm3) ARV
Feature of DRESS
at Initial Presentation
1st-Line Agents
Rechallenged
2nd-Line
Agents Used
Hypersensitivity Reactions
to 1st- and/or
2nd-Line Agents
CTCAE Criteria
Severity Grading of
Rechallenge Reaction
to 1st-Line Agents
1 36 M 63 Yes Rash, eosinophilia,
oedema, ×fever >38°C,
ALT > 5 ×ULN,
lymphadenopathy
RIF, INH, PZA,
ETH
MOX, ETH,
KNM
RIF: itch, morbilliform rash,
hepatitis eosinophilia, INH:
hepatitis, eosinophilia
Moderate
2 23 F 401 No Rash, eosinophilia,
oedema, fever >38°C,
ALT > 5 ×ULN,
lymphadenopathy
RIF, INH, PZA,
ETH
MOX, ETH,
KNM,
CPM,
RIF: itch, morbilliform rash,
hepatitis, eosinophilia,
oedema
MOX: morbilliform rash,
hepatitis, oedema, fever,
nausea, vomiting
Mild
3 31 F 457 No Rash, atypical lymphocytes,
oedema, fever >38°C,
ALT > 2 ×ULN,
lymphadenopathy
RIF, INH, PZA,
ETH
MOX, ETH,
KNM TER,
RIF: itch, morbilliform rash,
hepatitis, eosinophilia MOX:
intense itch morbilliform
rash, fever,
Mild
4 35 F 74 No Rash, eosinophilia,
oedema, fever >38°C,
ALT > 5 ×ULN,
lymphadenopathy
RIF, INH, PZA,
ETH
MOX, ETH,
KAN
RIF: itch, morbilliform rash,
oedema, INH: hepatitis,
fever, nausea, diarrhoea
Mild
5 49 M 32 No Rash, eosinophilia,
oedema, fever >38°C,
ALT > 5 ×ULN,
lymphadenopathy
RIF, INH, PZA,
ETH
MOX, TER,
KAN, ETH
RIF: morbilliform rash,
eosinophilia, fever,
diarrhoea, hypotension
MOX: eosinophilia, fever,
diarrhea
Severe
6 44 F 153 Yes Rash, eosinophilia,
anaemia, oedema, fever
>38°C, ALT > 5 × ULN,
lymphadenopathy
RIF, INH, PZA,
ETH
MOX, TER,
KAN, ETH
RIF: itch, morbilliform rash,
hepatitis eosinophilia,
oedema
PZA: itch morbilliform rash,
MOX and/or TER and/or
ETH: itch, erythematous
rash, hepatitis, oedema,
eosinophilia
Moderate
Abbreviations: ALT, alanine aminotransferase; AMK, amikacin; ARV, antiretroviral therapy; CADR, cutaneous adverse drug reactions; CPM, capreomycin; CTCAE, common terminology criteria
for adverse events (grade 1, mild; grade 2, moderate; grade 3, severe; grade 4, life-threatening; grade 5, death); DRESS, drug rash with eosinophilia and systemic symptoms; EMB, ethambutol;
ETH, ethionamide; INH, isoniazid; KNM, kanamycin; MOX, moxifloxacin; PZA, pyrazinamide; RIF, rifampicin; TER, terizidone; ULN, upper limit of normal.
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latter 3 cases needed standard 6 months of TB treatment after
successful replacement of rifampicin with rifabutin.
DISCUSSION
We report successful switch to rifabutin as an alternative to
rifampicin in 6 consecutive cases of rifampicin-associated
DRESS syndrome, effectively normalizing the duration of
therapy. The major concern in rechallenging with structurally
similar drugs is the possibility of cross-reactivity. Cross-
reactivity in DRESS syndrome is well described for several
structurally similar compounds such as aromatic anticonvul-
sants and sulfonamide antibiotics, the latter particularly in
persons infected with HIV [12]. However, there have been re-
ports of successful switch to rifabutin in rifampicin-associated
hepatotoxicity and hypersensitivity reactions, although a sig-
niﬁcant proportion reacted to both drugs [9, 10, 13]. Our ﬁnd-
ings suggest that that the 2 drugs in HIV-infected persons with
DRESS may not cross-react in the context of DRESS. It is still
unknown whether this applies to Stevens Johnson syndrome
and lichenoid drug eruption, other forms of CADR associated
with FLTD [3]. Larger studies are needed to conﬁrm these
ﬁndings.
A systematic review by Davies et al [14] found no signiﬁcant
differences in cure rates, relapse rates, and adverse event proﬁles
between those receiving either one of the 2 rifamycins, rifampi-
cin or rifabutin, in their treatment regimen. The 2 drugs have a
comparable efﬁcacy in the treatment of TB in persons infected
with HIV [15]. However, drug interactions between rifabutin
and ART have to be considered in this subgroup. Efavirenz,
which forms the backbone of 2nd-line ART regimen in South
Africa, signiﬁcantly reduces plasma levels of rifabutin. Thus,
higher doses of rifabutin are required when the drug is used
with efavirenz [16]. We used this higher dosing in all of our 6
patients who also initiated an efavirenz-containing regimen.
The switch to rifabutin in our patients facilitated an optimal
treatment regimen despite the loss of an important FLTD.
Cross-resistance between the 2 rifamycins, estimated to go up
to 90%, is another concern in re-exposing a patient to a poten-
tially life-threatening rechallenge reaction [17]. Therefore, it is
prudent to ascertain that rifampicin-sensitive strains of TB are
being treated, as was the case in 5 of our cases. The other case
with disseminated disease was initiated on therapy based on
clinical features only.
The major limitation of our study is the small sample size.
Conﬁrmation of rifampicin-associated DRESS syndrome by di-
agnostic rechallenge is still infrequently performed considering
the severity of the reaction. Larger studies in multiple centers
are needed to conﬁrm our ﬁndings. It is also not clear whether
these ﬁndings are applicable in non-HIV-infected persons or
other severe forms of CADRs.
CONCLUSIONS
In summary, we show that rifabutin is a viable replacement in
rifampicin-associated DRESS syndrome in patients coinfected
with TB and HIV. Our ﬁndings, if conﬁrmed in larger cohorts
and different clinical settings, will allow patients with rifampicin-
associated DRESS to remain on optimum treatment, improving
cure rates and compliance.
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